Surovatamig + R-CHOP + R-CVP + BR
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated Follicular Lymphoma
Conditions
Untreated Follicular Lymphoma
Trial Timeline
Aug 7, 2024 → Nov 26, 2031
NCT ID
NCT06549595About Surovatamig + R-CHOP + R-CVP + BR
Surovatamig + R-CHOP + R-CVP + BR is a phase 3 stage product being developed by AstraZeneca for Untreated Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06549595. Target conditions include Untreated Follicular Lymphoma.
What happened to similar drugs?
1 of 3 similar drugs in Untreated Follicular Lymphoma were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06549595 | Phase 3 | Recruiting |
Competing Products
15 competing products in Untreated Follicular Lymphoma